In first graph of release dated July 27, 2009, date should be Wednesday,
August 5 (sted Tuesday, August 4).
The corrected release reads:
ENZON TO PRESENT AT BMO FOCUS ON HEALTHCARE CONFERENCE
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Jeffrey
H. Buchalter, Enzon’s president and chief executive officer, will
present at the 2009 BMO Capital Markets 9th Annual Focus on
Healthcare Conference, which is being held August 5th in New
York City. Enzon’s presentation will take place at 9:30 a.m. EST on
Wednesday, August 5, 2009. The presentation will be webcast. Interested
parties can access the webcast information by going to the events page
that is under shareholder information on Enzon’s website at www.enzon.com.
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to
the development, manufacturing, commercialization of important medicines
for patients with cancer and other life-threatening conditions. Enzon
has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet®
and Adagen®. The Company’s drug development programs utilize several
cutting-edge approaches, including its industry-leading PEGylation
technology platform used to create product candidates with benefits such
as reduced dosing frequency and less toxicity. Enzon’s PEGylation
technology was used to develop two of its products, Oncaspar and Adagen,
and has created a royalty revenue stream from licensing partnerships for
other products developed using the technology. Enzon also engages in
contract manufacturing for several pharmaceutical companies to broaden
the Company’s revenue base. Further information about Enzon and this
press release can be found on the Company’s web site at www.enzon.com.
Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777
EVP,
Finance and Chief Financial Officer
